BioSpace News Archive

Drug Development

CDMOs Face Headwinds in 2023, Look to Slow Recovery

BioSpace spoke to analysts and players in the contract manufacturing and development organizations space to assess the challenges this year and what lies ahead in 2024.

November 29, 2023
·
6 min read
·
Tyler Patchen
Business

Lilly Puts Potential $660M on the Line for Protein-Protein Interaction Blockers

In a deal with Tokyo-based PRISM BioLab, Eli Lilly will gain access to the Japanese biotech’s proprietary platform to develop small molecule inhibitors of protein-protein interactions.

November 29, 2023
·
2 min read
·
Tristan Manalac
Business

Boehringer Ingelheim Targets Stroma-Rich Cancers in Potential $509M AI Deal

The pharma giant is paying $9 million upfront to Phenomic AI to develop targets for stroma-rich cancers, some of the hardest cancers to treat, utilizing its single-cell RNA computing platform.

November 29, 2023
·
2 min read
·
Kate Goodwin
Novartis Raises Growth Target, Trims Pipeline Under ‘Pure-Play’ Strategy

The Swiss pharma is adopting a more streamlined strategy focusing on core therapeutic areas: cardiovascular, immunology, neuroscience and oncology, as well as renal and metabolic diseases.

November 29, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Real-World Data Shows Lilly’s Tirzepatide Beats Novo’s Semaglutide at Weight Loss

Using electronic health records, healthcare analytics firm Truveta contends that Eli Lilly’s Mounjaro (tirzepatide) could achieve stronger and faster weight loss than Novo Nordisk’s Ozempic (semaglutide).

November 29, 2023
·
2 min read
·
Tristan Manalac
Deals

Deals, Dupixent and GLP-1 drug shortages

This week on The Weekly we talk struggles with ⁠GLP-1 drug shortages⁠ and what that might mean for Novo and Lilly competitors; Regeneron and Sanofi positive results for ⁠⁠⁠Dupixent⁠⁠⁠ in COPD. Plus, Merck ⁠buys Caraway⁠, Beigene’s ⁠deal⁠ with Ensem, ⁠ups⁠ and ⁠downs⁠ for Flagship.

November 29, 2023
·
1 min read
·
Lori Ellis
Verve Stock Takes a Hit on $148M Offering to Public, Lilly

After Verve Therapeutics recently announced gene editing therapy results, the company is offering up its stock to the public and Eli Lilly. However, the stock was down 13% Wednesday on the news.

November 29, 2023
·
2 min read
·
Tyler Patchen
RetinAI Joins Forces with Stephen J. Ryan Initiative for Macular Research (RIMR) AMD Consortium to Forge a Global Retinal Imaging initiative Targeting Research in AMD

RetinAI Medical AG (“RetinAI”), a leader in clinical and imaging data management software and advanced analytics using artificial intelligence (AI), announces that they are now joining the Ryan Initiative for Macular Research (RIMR)

November 29, 2023
·
4 min read
Addex Reports Q3 2023 Financial Results and Provides Corporate Update

Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, reported its Q3 2023 financial results for the period ended September 30, 2023 and provides a corporate update.

November 29, 2023
·
7 min read
Drug Development

Bio-Thera Solutions Announces Positive Results from Phase 3 Study of BAT2206, a Proposed Biosimilar Referencing Stelara®

Bio-Thera Solutions, Ltd., a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets, announced results from the Phase 3 study of BAT2206, a proposed biosimilar referencing Stelara®.

November 29, 2023
·
5 min read